AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie orilissa/Oriahnn [legacy through FY21] — Worldwide net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, Q4 2021
39
Period ended Dec 31, 2021
Change on a year earlier
+2.6%
38 in Q4 2020
History
11 quarters
Since Q2 2019
Sources
6
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Orilissa/Oriahnn [legacy through FY21] — Worldwide net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2021 | Dec 31, 2021 | 39 | +2.6% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2021 | Sep 30, 2021 | 38 | +52.0% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 38 | +22.6% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2021 | Mar 31, 2021 | 30 | -3.2% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2020 | Dec 31, 2020 | 38 | +11.8% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2020 | Sep 30, 2020 | 25 | -7.4% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2020 | Jun 30, 2020 | 31 | +63.2% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2020 | Mar 31, 2020 | 31 | – | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 34 | – | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2019 | Sep 30, 2019 | 27 | – | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2019 | Jun 30, 2019 | 19 | – | Form 10-Q (filed 2020-08-04) ↗ |
Breakdown
What makes up orilissa/oriahnn [legacy through fy21] — worldwide net revenues ($m)
- Orilissa/Oriahnn [legacy through FY21] — U.S. net revenues ($M)37 · Q4 2021
- Orilissa/Oriahnn [legacy through FY21] — International net revenues ($M)2 · Q4 2021
- Orilissa/Oriahnn [legacy through FY21] — Worldwide reported growth YoY (%)4.8% · Q4 2021
- Orilissa/Oriahnn [legacy through FY21] — Worldwide operational (constant-currency) growth YoY (%)4.6% · Q4 2021
Cite this data
StockData. (2026). AbbVie Orilissa/Oriahnn [legacy through FY21] — Worldwide net revenues ($M) ($M), quarterly Q2 2019–Q4 2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/orilissa_oriahnn_ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.